Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01795313 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
A Phase 1 study, sponsored by James Felker.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01795313: Clinical Trial Phase 1 study, sponsored by James Felker.
NCT01795313 is a Phase 1 study that was terminated before completion, run by James Felker. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01795313, a Phase 1 study, was terminated before completion, sponsored by James Felker.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
Primary Outcome
Grade 3 or 4 non-hematological toxicities.
Interventions
- DRUG Imiquimod
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
- OTHER enzyme-linked immunosorbent assay
- BIOLOGICAL HLA-A2 restricted synthetic tumor antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-08 |
| Est. Completion | 2025-12-03 |
| Phase | Phase 1 |
Why NCT01795313 stopped before completion
NCT01795313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 5 interventions - of which Imiquimod is the first listed.
NCT01795313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01795313 about?
NCT01795313 is a clinical study titled "Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod". The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
What is the current status of trial NCT01795313?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2012-08. Estimated completion is 2025-12-03.
What interventions are being tested in trial NCT01795313?
The interventions under investigation include: Imiquimod (DRUG), immunohistochemistry staining method (OTHER), flow cytometry (OTHER), enzyme-linked immunosorbent assay (OTHER), HLA-A2 restricted synthetic tumor antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01795313?
This trial is sponsored by James Felker, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01795313's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia